Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Antibody / Recombinant Antibody

Anti-GRB7 Antibody (R2F43)

Catalog #:   RHG80101 Specific References (34) DATASHEET
Host species: Rabbit
Isotype: IgG
Applications: IHC, WB
Accession: Q14451
Overview

Catalog No.

RHG80101

Species reactivity

Human, Mouse, Rat

Host species

Rabbit

Isotype

IgG

Clonality

Monoclonal

Tested applications

IHC: 1:100-1:200, WB: 1:1000-1:2000

Target

GRB7, Growth factor receptor-bound protein 7, GRB7 adapter protein, Epidermal growth factor receptor GRB-7, B47

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

Q14451

Applications

IHC, WB

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 0.05% BSA, 50% Glycerol, 0.05% Sodium azide.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 4 ℃ for frequent use. Store at -20 ℃ for twelve months from the date of receipt.

Clone ID

R2F43

Data Image
  • Western blot
    Western blot analysis of GRB7 expression in A431 cell lysate.
  • Western blot
    All lanes use the Antibody at 1:2K dilution for 1 hour at room temperature.
References

Characterization of HER2-Low Breast Tumors among a Cohort of Colombian Women., PMID:39335113

Detecting Human Epidermal Growth Factor Receptor 2 (HER2) Amplification: Proof of Concept of an Alternative Approach., PMID:37809181

Prognostic value of ALK overexpression and molecular abnormalities in high-grade serous ovarian carcinoma., PMID:37522200

Randomized, open-label, phase 2 study of andecaliximab plus nivolumab versus nivolumab alone in advanced gastric cancer identifies biomarkers associated with survival., PMID:34893523

GRB7 is an oncogenic driver and potential therapeutic target in oesophageal adenocarcinoma., PMID:32737994

Phase II Feasibility and Biomarker Study of Neoadjuvant Trastuzumab and Pertuzumab With Chemoradiotherapy for Resectable Human Epidermal Growth Factor Receptor 2-Positive Esophageal Adenocarcinoma: TRAP Study., PMID:31809243

Dopamine and cAMP-regulated phosphoprotein 32 kDa (DARPP-32) and survival in breast cancer: a retrospective analysis of protein and mRNA expression., PMID:31740718

Genomic characterization of HER2-positive breast cancer and response to neoadjuvant trastuzumab and chemotherapy-results from the ACOSOG Z1041 (Alliance) trial., PMID:28453704

An Integrative Analysis to Identify Driver Genes in Esophageal Squamous Cell Carcinoma., PMID:26465158

Syk Is Recruited to Stress Granules and Promotes Their Clearance through Autophagy., PMID:26429917

c-Abl modulates tumor cell sensitivity to antibody-dependent cellular cytotoxicity., PMID:25300860

Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31., PMID:24262440

Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer., PMID:24075779

"Omics" of HER2-positive breast cancer., PMID:23421906

The HER2 amplicon includes several genes required for the growth and survival of HER2 positive breast cancer cells., PMID:23253899

Protein pathway activation mapping reveals molecular networks associated with antiestrogen resistance in breast cancer cell lines., PMID:22328489

Correlation between gene expression of IGF-1R pathway markers and cetuximab benefit in metastatic colorectal cancer., PMID:22294722

A gene on the HER2 amplicon, C35, is an oncogene in breast cancer whose actions are prevented by inhibition of Syk., PMID:20628393

EGF-induced Grb7 recruits and promotes Ras activity essential for the tumorigenicity of Sk-Br3 breast cancer cells., PMID:20622016

Growth factor receptor-bound protein-7 (Grb7) as a prognostic marker and therapeutic target in breast cancer., PMID:19717535

The cell migration protein Grb7 associates with transcriptional regulator FHL2 in a Grb7 phosphorylation-dependent manner., PMID:18853468

Combination treatment with Grb7 peptide and Doxorubicin or Trastuzumab (Herceptin) results in cooperative cell growth inhibition in breast cancer cells., PMID:17426702

PREL1 provides a link from Ras signalling to the actin cytoskeleton via Ena/VASP proteins., PMID:16783873

Disease-specific proteins from rheumatoid arthritis patients., PMID:16778393

Lipid-protein interactions of growth factor receptor-bound protein 14 in insulin receptor signaling., PMID:16300394

PREL1 provides a link from Ras signalling to the actin cytoskeleton via Ena/VASP proteins., PMID:15642358

ERBB2 amplifications in esophageal adenocarcinoma., PMID:15511476

NIK is a component of the EGF/heregulin receptor signaling complexes., PMID:12853971

Adaptor signalling proteins Grb2 and Grb7 are recruited by human G6f, a novel member of the immunoglobulin superfamily encoded in the MHC., PMID:12852788

Constitutive and growth factor-regulated phosphorylation of caveolin-1 occurs at the same site (Tyr-14) in vivo: identification of a c-Src/Cav-1/Grb7 signaling cassette., PMID:11075810

Interaction of the Grb7 adapter protein with Rnd1, a new member of the Rho family., PMID:10664463

Lack of MHC class I surface expression on neoplastic cells and poor activation of the secretory pathway of cytotoxic cells in oral squamous cell carcinomas., PMID:10555762

Granzyme B immunoreactivity in T/natural killer cell lymphomas., PMID:9409191

Cloning and characterization of GRB14, a novel member of the GRB7 gene family., PMID:8647858

Datasheet

Document Download

Anti-GRB7 Antibody (R2F43).pdf

 

$ 290
Product specifications
50 μg 290 100 μg 484

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Anti-GRB7 Antibody (R2F43) [RHG80101]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only